Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes

Clinical and Experimental Ophthalmology

Volumn 38, Issue 1, 2010, Pages 57-64

  Abu El Asrar, Ahmed M ^a   Missotten, Luc ^b   Geboes, Karel ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Advanced glycation end product; Diabetic retinopathy; Integrin; Transforming growth factor ; Tumour necrosis factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHAVBETA5 INTEGRIN; CD34 ANTIGEN; INTEGRIN; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; STROMA CELL;

ANTIGENS, CD34; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; EPIRETINAL MEMBRANE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRINS; KI-67 ANTIGEN; RETINAL VESSELS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950929861     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02194.x     Document Type: Article

References (38)

1. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003, 75:95-108.
2. Wautier JL, Guilausseau PJ. Advanced glycation end products and their receptors and diabetic angiopathy. Diabetes Metab 2001, 27:535-42.
3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-21.
4. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
5. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001, 38:S100-S106.
6. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994, 45:491-503.
7. Gao X, Belmadani S, Picchi A. Tumor necrosis factor-α induces endothelial dysfunction in Leprdb mice. Circulation 2007, 115:245-54.
8. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008, 295:H491-H498.
9. Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells. Kidney Int 2004, 66:1099-106.
10. Makino N, Maeda T, Sugano M, Satoh S, Watanabe R, Abe N. High serum TNF-α level in type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications 2005, 19:347-55.
11. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-β signal transduction in angiogenesis and vascular disorders. Chest 2005, 128:585S-90S.
12. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells medicated by protein Kinase C and transforming growth factor-beta. J Lab Clin Med 2001, 138:59-68.
13. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258.
14. Akiyama SK. Integrins in cell adhesion and signaling. Hum Cell 1996, 9:181-6.
15. Riiegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003, 60:1135-57.
16. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in nonglycemic rats. Mol Cell Biol Res Commun 2000, 3:380-8.
17. Yamagishi S, Yonekura H, Yamamoto Y. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997, 272:8723-30.
18. Okamoto T, Yamagishi S, Inagaki Y. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002, 16:1928-30.
19. Okamoto T, Tanaka S, Stan AC. Advanced glycation end products induce angiogenesis in vivo. Microvasc Res 2002, 63:186-95.
20. Stitt A, Gardiner TA, Anderson NL. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002, 51:2826-32.
21. Bhatwadekar A, Glenn JV, Figarola JL. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 2008, 92:545-7.
22. Kaji Y, Usui T, Ishida S. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007, 48:858-65.
23. Dolhofer-Bliosener R, Lechner B, Gerbitz KD. Possible significance of advanced glycation end products in serum in end-stage renal disease and in late complications of diabetes. Eur J Clin Chem Clin Biochem 1996, 34:355-61.
24. Ma J, Wang Q, Fei T, Han JDJ, Chen YG. MCP-1 mediates TGF-β induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007, 1909:987-94.
25. Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, Missotten L, Opdenakker G, Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol 2007, 27:11-22.
26. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 2006, 17:155-65.
27. Joussen AM, Poulaki V, Le ML. A central role of inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004, 18:1450-2.
28. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications 2008, 22:309-16.
29. Ben-Mahmud BM, Mann GE, Datti A, Orlacchio A, Kohner EM. Tumor necrosis factor-α in diabetic plasma increases the activity of Core 2 GIcNAc-T and adherence of human leukocytes to retinal endothelial cells. Significance of Core 2 GIcNAc-T in diabetic retinopathy. Diabetes 2004, 53:2968-76.
30. Clauss M, Sunderkötter C, Sveinbjömsson B. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 2001, 97:1321-9.
31. Sainson RCA, Johnston DA, Chu HC. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 2008, 11:4997-5007.
32. Gao B, Saba TM, Tsan M-F. Role of αvβ3-integrin in TNF-α induced endothelial cell migration. Am J Physiol Cell Physiol 2002, 283:C1196-C1205.
33. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995, 270:1500-2.
34. Joussen AM, Poulaki V, Mitsiades N. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002, 16:438-40.
35. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-71.
36. Brooks PC, Montgomery AM, Rosenfeld M. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-64.
37. Wilkinson-Berka JL, Jones D, Taylor G. SB-267268, a nonpeptide antagonist of αvβ5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2006, 47:1600-5.
38. Santulli RJ, Kinney WA, Ghosh S. Studies with an orally bioavailable αv integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther 2008, 324:894-901.